Ownership and insider activity for Avalo Therapeutics, Inc. (AVTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT.
Price
| Price | $16.58 |
| Market Cap | $872M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-10 | Sullivan Christopher Ryan | M-Exempt | 10,185 | $82K |
| 2026-09-10 | Sullivan Christopher Ryan | M-Exempt | 10,185 | $82K |
| 2026-09-10 | Sullivan Christopher Ryan | S-Sale | 10,185 | $179K |
| 2026-08-28 | Doyle Mittie | M-Exempt | 679 | $5K |
| 2026-08-28 | Doyle Mittie | M-Exempt | 679 | $5K |
| 2026-08-28 | Doyle Mittie | S-Sale | 679 | $14K |
| 2026-08-17 | Sullivan Christopher Ryan | M-Exempt | 37,945 | $375K |
| 2026-08-17 | Sullivan Christopher Ryan | M-Exempt | 2,876 | $28K |
| 2026-08-18 | Sullivan Christopher Ryan | M-Exempt | 31,031 | $307K |
| 2026-08-17 | Sullivan Christopher Ryan | M-Exempt | 2,876 | $28K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.1M | $2.5M | $10.6M | $3.6M | $18.9M | $54.6M | $13.2M | $7.4M | $134.5M | $15.9M |
| Short-term Investments | 0 | 0 | 0 | $7.6M | 0 | 0 | 0 | 0 | 0 | $82.5M |
| Receivables | $132472 | $2.9M | $6.1M | $5.2M | $4.4M | $4.8M | $1.9M | $136000 | $611000 | 0 |
| Inventory | $11000 | $382153 | $1.1M | $21334 | $3000 | $38000 | $20000 | 0 | 0 | 0 |
| Total Current Assets | $5.7M | $11.0M | $21.9M | $17.7M | $26.0M | $61.8M | $16.4M | $8.4M | $138.9M | $105.3M |
| Property, Plant & Equipment | $43000 | $44612 | $586512 | $1.4M | $1.6M | $2.7M | $2.4M | $2.0M | $1.2M | $460000 |
| Goodwill | 0 | $14.3M | $16.4M | $14.4M | $14.4M | $14.4M | $14.4M | $10.5M | $10.5M | $10.5M |
| Intangible Assets | 0 | $17.7M | $31.2M | $2.4M | $1.6M | $38000 | 0 | 0 | 0 | 0 |
| Total Assets | $5.8M | $43.1M | $70.3M | $36.1M | $43.8M | $80.2M | $33.4M | $21.0M | $150.7M | $116.5M |
| Accounts Payable | $1.0M | $1.3M | $1.4M | $2.1M | $2.6M | $3.4M | $2.9M | $446000 | $283000 | $137000 |
| Short-term Debt | $2.4M | 0 | 0 | 0 | 0 | 0 | $5.9M | 0 | 0 | 0 |
| Total Current Liabilities | $4.3M | $11.4M | $26.2M | $12.2M | $15.2M | $19.9M | $22.1M | $4.6M | $7.0M | $12.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $32.8M | $13.5M | 0 | 0 | $2.0M |
| Total Liabilities | $5.6M | $15.3M | $49.3M | $15.1M | $19.2M | $57.1M | $44.3M | $13.7M | $17.7M | $33.4M |
| Retained Earnings | -$70.0M | -$58.2M | -$98.2M | -$114.3M | -$177.8M | -$262.2M | -$303.8M | -$335.1M | -$370.3M | -$448.5M |
| Total Equity | $207000 | $27.9M | $20.9M | $21.0M | $24.6M | $23.1M | -$10.9M | $7.3M | $133.0M | $83.0M |
| Total Debt | $2.4M | 0 | $15.4M | $155815 | $426000 | $33.3M | $19.9M | $537000 | $568000 | $2.4M |
| Net Debt | -$2.8M | -$2.5M | $4.7M | -$11.1M | -$18.5M | -$21.3M | $6.8M | -$6.9M | -$134.0M | -$95.9M |
| Working Capital | $1.4M | -$415070 | -$4.3M | $5.6M | $10.8M | $42.0M | -$5.7M | $3.8M | $131.9M | $92.3M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 19.31 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -2.13 |
Profitability
| Return on Equity | -58.03% |
| Return on Invested Capital | -19.44% |
| Return on Assets | -20.44% |
| Gross Margin | -16861.02% |
| Operating Margin | -154844.07% |
| Net Margin | -170055.93% |
Related companies: AARD · BDTX · CHRS · CRBU · ENTA · EPRX · IVA
Explore sector: Healthcare · Biotechnology
More sections of AVTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks